Is intranasal azelastine safe for a stable asthmatic patient aged over 12 years?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Azelastine Safe in Asthma?

Yes, intranasal azelastine is safe for stable asthmatic patients aged 12 years and older with allergic rhinitis. The FDA label explicitly states that oral azelastine has been safely administered to over 1,400 asthmatic subjects, supporting the safety of administering intranasal azelastine to allergic rhinitis patients with asthma 1.

Evidence Supporting Safety in Asthma

  • Direct safety data: The FDA clinical pharmacology section documents that azelastine has been tested and proven safe in a large asthma population, with no contraindications listed for asthmatic patients 1.

  • Mechanism of safety: Azelastine is a second-generation H1-receptor antagonist with minimal systemic absorption (approximately 40% bioavailability) when administered intranasally, limiting systemic effects that could theoretically impact asthma control 1.

Age-Specific Approval and Dosing

  • For patients ≥12 years: Azelastine 0.1% (Astelin) is approved at 1-2 sprays per nostril twice daily, and azelastine 0.15% (Astepro) is approved at the same dosing regimen 2.

  • Not approved for children <6 years: The American Academy of Otolaryngology-Head and Neck Surgery explicitly states that intranasal azelastine is not approved for children younger than 5-6 years and should not be prescribed in this age group 2, 3.

Common Side Effects to Counsel Patients About

  • Bitter taste is the most common adverse event, occurring in 8-9% of patients 4.

  • Somnolence rates are low: Recent studies show somnolence occurs in only 0.4-3% of patients, comparable to placebo rates, despite early studies reporting rates around 11% 2, 5. In one large trial, somnolence was reported by only 1.7% of patients on azelastine 0.15%, 0.6% on azelastine 0.10%, and 0.6% on placebo 4.

  • Epistaxis and nasal discomfort occur in approximately 4-5% of patients 6.

Clinical Efficacy in Asthmatic Patients with Allergic Rhinitis

  • Rapid onset of action: Azelastine works within 15-30 minutes, significantly faster than oral antihistamines 5, 4.

  • Effective for all nasal symptoms: Unlike oral antihistamines, intranasal azelastine effectively treats nasal congestion in addition to rhinorrhea, sneezing, and itching 2, 5.

  • Superior to oral antihistamines: Intranasal antihistamines show equality or superiority to oral antihistamines in well-designed randomized controlled trials, with particular benefit for nasal congestion 2.

Combination Therapy for Severe Symptoms

  • Add to intranasal corticosteroids if needed: For moderate-to-severe allergic rhinitis inadequately controlled by intranasal corticosteroids alone, adding azelastine provides >40% relative improvement compared to either agent alone 7, 5.

  • Particularly beneficial for treatment failures: This combination is especially useful for patients who have failed previous oral antihistamine therapy 5.

Important Caveats

  • No contraindications for asthma: The FDA label lists no contraindications related to asthma or respiratory disease 1.

  • Monitor for somnolence initially: Although rates are low, patients should be counseled about potential drowsiness when initiating therapy, particularly if operating machinery or driving 5.

  • Proper administration technique: Patients should be taught correct spray technique to minimize local side effects and maximize efficacy 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Azelastine Nasal Spray in Children Younger Than 5 Years

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Azelastine Efficacy and Safety for Allergic Rhinitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Intranasal Steroid Recommendations for Allergic Rhinitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.